A share price of Wave Life Sciences Ltd [WVE] is currently trading at $17.77, down -2.63%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The WVE shares have gain 14.35% over the last week, with a monthly amount glided 139.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Wave Life Sciences Ltd [NASDAQ: WVE] stock has seen the most recent analyst activity on December 12, 2025, when Wedbush reiterated its Outperform rating and also boosted its price target to $33 from $20. Previously, RBC Capital Mkts upgraded its rating to Outperform on December 09, 2025, and kept the price target unchanged to $27. On October 20, 2025, Wells Fargo initiated with an Overweight rating and assigned a price target of $18 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $19 on August 04, 2025. Oppenheimer initiated its recommendation with an Outperform and recommended $24 as its price target on July 28, 2025. Citigroup started tracking with a Buy rating for this stock on July 16, 2025, and assigned it a price target of $16.
Wave Life Sciences Ltd experienced fluctuations in its stock price throughout the past year between $5.28 and $21.73. Currently, Wall Street analysts expect the stock to reach $31.54 within the next 12 months. Wave Life Sciences Ltd [NASDAQ: WVE] shares were valued at $17.77 at the most recent close of the market. An investor can expect a potential return of 77.49% based on the average WVE price forecast.
Analyzing the WVE fundamentals
Trailing Twelve Months sales for Wave Life Sciences Ltd [NASDAQ:WVE] were 109.23M which represents 199.11% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.24%, Pretax Profit Margin comes in at -1.12%, and Net Profit Margin reading is -1.12%. To continue investigating profitability, this company’s Return on Assets is posted at -4.71, Equity is -0.73 and Total Capital is 2.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.50 points at the first support level, and at 17.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.22, and for the 2nd resistance point, it is at 18.66.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Wave Life Sciences Ltd [NASDAQ:WVE] is 2.51. In addition, the Quick Ratio stands at 2.51 and the Cash Ratio stands at 2.28. Considering the valuation of this stock, the price to sales ratio is 29.77, the price to book ratio is 22.87.
Transactions by insiders
Recent insider trading involved GSK plc, 10% Owner, that happened on Dec 11 ’25 when 1.47 million shares were purchased. Director, Rawcliffe Adrian completed a deal on Dec 08 ’25 to sell 42000.0 shares. Meanwhile, Director Wagner Heidi L sold 14000.0 shares on Dec 08 ’25.
